Corticosteroid therapy for COVID-19 : A systematic review and meta-analysis of randomized controlled trials
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc..
BACKGROUND: Corticosteroid treatment is an effective and common therapeutic strategy for various inflammatory lung pathologies and may be an effective treatment for coronavirus disease 2019 (COVID-19). The purpose of this systematic review and meta-analysis of current literature was to investigate the clinical outcomes associated with corticosteroid treatment of COVID-19.
METHODS: We systematically searched PubMed, medRxiv, Web of Science, and Scopus databases through March 10, 2021 to identify randomized controlled trials (RCTs) that evaluated the effects of corticosteroid therapies for COVID-19 treatment. Outcomes of interest were mortality, need for mechanical ventilation, serious adverse events (SAEs), and superinfection.
RESULTS: A total of 7737 patients from 8 RCTs were included in the quantitative meta-analysis, of which 2795 (36.1%) patients received corticosteroids plus standard of care (SOC) while 4942 (63.9%) patients received placebo and/or SOC alone. The odds of mortality were significantly lower in patients that received corticosteroids as compared to SOC (odds ratio [OR] = 0.85 [95% CI: 0.76; 0.95], P = .003). Corticosteroid treatment reduced the odds of a need for mechanical ventilation as compared to SOC (OR = 0.76 [95% CI: 0.59; 0.97], P = .030). There was no significant difference between the corticosteroid and SOC groups with regards to SAEs and superinfections.
CONCLUSION: Corticosteroid treatment can reduce the odds for mortality and the need for mechanical ventilation in severe COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:100 |
|---|---|
| Enthalten in: |
Medicine - 100(2021), 20 vom: 21. Mai, Seite e25719 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pulakurthi, Yashwitha Sai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 24.05.2021 Date Revised 03.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000025719 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325606447 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325606447 | ||
| 003 | DE-627 | ||
| 005 | 20231225192809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000025719 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325606447 | ||
| 035 | |a (NLM)34011029 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pulakurthi, Yashwitha Sai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corticosteroid therapy for COVID-19 |b A systematic review and meta-analysis of randomized controlled trials |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2021 | ||
| 500 | |a Date Revised 03.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a BACKGROUND: Corticosteroid treatment is an effective and common therapeutic strategy for various inflammatory lung pathologies and may be an effective treatment for coronavirus disease 2019 (COVID-19). The purpose of this systematic review and meta-analysis of current literature was to investigate the clinical outcomes associated with corticosteroid treatment of COVID-19 | ||
| 520 | |a METHODS: We systematically searched PubMed, medRxiv, Web of Science, and Scopus databases through March 10, 2021 to identify randomized controlled trials (RCTs) that evaluated the effects of corticosteroid therapies for COVID-19 treatment. Outcomes of interest were mortality, need for mechanical ventilation, serious adverse events (SAEs), and superinfection | ||
| 520 | |a RESULTS: A total of 7737 patients from 8 RCTs were included in the quantitative meta-analysis, of which 2795 (36.1%) patients received corticosteroids plus standard of care (SOC) while 4942 (63.9%) patients received placebo and/or SOC alone. The odds of mortality were significantly lower in patients that received corticosteroids as compared to SOC (odds ratio [OR] = 0.85 [95% CI: 0.76; 0.95], P = .003). Corticosteroid treatment reduced the odds of a need for mechanical ventilation as compared to SOC (OR = 0.76 [95% CI: 0.59; 0.97], P = .030). There was no significant difference between the corticosteroid and SOC groups with regards to SAEs and superinfections | ||
| 520 | |a CONCLUSION: Corticosteroid treatment can reduce the odds for mortality and the need for mechanical ventilation in severe COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Pederson, John M |e verfasserin |4 aut | |
| 700 | 1 | |a Saravu, Kavitha |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Nitin |e verfasserin |4 aut | |
| 700 | 1 | |a Balasubramanian, Prasanth |e verfasserin |4 aut | |
| 700 | 1 | |a Kamrowski, Shelby |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Vegivinti, Charan Thej Reddy |e verfasserin |4 aut | |
| 700 | 1 | |a Dibas, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Reierson, Natalie L |e verfasserin |4 aut | |
| 700 | 1 | |a Pisipati, Sailaja |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, Betsy Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Selvan, Pragadeesh Thamarai |e verfasserin |4 aut | |
| 700 | 1 | |a Dmytriw, Adam A |e verfasserin |4 aut | |
| 700 | 1 | |a Keesari, Praneeth Reddy |e verfasserin |4 aut | |
| 700 | 1 | |a Sriram, Varsha |e verfasserin |4 aut | |
| 700 | 1 | |a Chittajallu, Spandana |e verfasserin |4 aut | |
| 700 | 1 | |a Brinjikji, Waleed |e verfasserin |4 aut | |
| 700 | 1 | |a Katamreddy, Rewanth R |e verfasserin |4 aut | |
| 700 | 1 | |a Chibbar, Richa |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Amber R |e verfasserin |4 aut | |
| 700 | 1 | |a Malpe, Manashree |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Hemant K |e verfasserin |4 aut | |
| 700 | 1 | |a Kallmes, Kevin M |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Ameer E |e verfasserin |4 aut | |
| 700 | 1 | |a Evanson, Kirk W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 100(2021), 20 vom: 21. Mai, Seite e25719 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:100 |g year:2021 |g number:20 |g day:21 |g month:05 |g pages:e25719 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000025719 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 100 |j 2021 |e 20 |b 21 |c 05 |h e25719 | ||